Biotia Raises $9M for Infectious Disease Diagnostics

A laboratory can produce a more detailed answer and still face the harder commercial questions: who pays for it, when a clinician orders it, and how the result changes care. Biotia has raised an oversubscribed $9M financing to scale the operating system around its clinical metagenomic diagnostics, from laboratory capacity and reimbursement to new tests in women's health and orthopedics. The financing is aimed at the handoffs between a strong assay, a working laboratory, a clinician, a claim, and a patient.

The New York company announced the financing on October 1, 2026. Biotia did not disclose a formal round label, lead investor, valuation, security, or detailed terms. The company said the capital will help scale its New York City laboratory, expand its test menu, pursue reimbursement, increase clinician access, and move further into orthopedic diagnostics.

What Biotia financed

Biotia is a spinout of the Jacobs Technion-Cornell Institute at Cornell Tech, built from research led by co-founders Niamh O'Hara, PhD, now CEO, and Christopher Mason, PhD, now Global Director. CTO David Danko, PhD, leads the software and bioinformatics work behind the company's diagnostic pipelines. Biotia operates a high-complexity, CLIA-certified laboratory in New York City and combines metagenomic next-generation sequencing with a curated pathogen database and machine-learning software.

The company's flagship product, BIOTIA-ID Urine, is designed for recurrent and complicated urinary tract infections. Instead of culturing only the organisms that grow under standard laboratory conditions or testing a fixed panel of targets, the assay sequences microbial genetic material in the sample and uses Biotia's BIOTIA-DX pipeline to identify pathogens and antimicrobial-resistance markers.

That mechanism matters because difficult infections often arrive with ambiguity. A patient can have persistent symptoms, a negative culture, prior antibiotic exposure, or several organisms that are hard to distinguish as infection, colonization, or contamination. More genomic information can improve the investigation, but it also raises the bar for assay validation, interpretation, clinician education, and responsible treatment decisions.

The evidence behind BIOTIA-ID Urine

A 2026 peer-reviewed study in Microbiology Spectrum evaluated the BIOTIA-ID workflow across 1,470 urine specimens and more than 14,500 analytes. Following comparator adjudication, the clinical accuracy study reported 97.2% sensitivity and 99.6% specificity. The study also evaluated antimicrobial-resistance markers in a subset of 332 clinical specimens.

Those results support the assay's analytical and clinical performance under the study design. They do not establish that every additional organism detected is clinically meaningful, that every patient outcome improves, or that sequencing replaces physician judgment. Biotia's own evidence materials emphasize controls, curated references, and machine-learning classification intended to reduce false positives, which is central to making a broader detection method useful rather than merely noisy.

The BIOTIA-ID Urine evidence library says the test is available in all 50 states. The assay is a laboratory-developed test approved by the New York State Department of Health Clinical Laboratory Evaluation Program and performed in Biotia's CLIA-certified laboratory. Biotia's product disclaimer says the test has not been cleared or approved by the FDA, a distinction that matters when readers interpret the word "approved" in diagnostic announcements.

Why reimbursement belongs in the funding story

Biotia received a test-specific AMA Proprietary Laboratory Analyses code in 2025. A billing code creates a more precise way to submit and adjudicate claims, but it does not guarantee insurer coverage or payment. Biotia currently tells consumers that it does not accept insurance for the at-home collection pathway, which helps explain why reimbursement work appears beside laboratory scale and product development in the new financing plan.

Clinical diagnostics are bought through a chain of decisions. A laboratory must produce a defensible result, a clinician must know when to order it, a patient must be able to access it, and a payer must decide how the service fits coverage policy. The $9M gives Biotia more room to work on those handoffs without pretending that a strong accuracy table alone completes the commercial job.

From women's health into orthopedics

Biotia said the financing will support additional diagnostics in women's health, where recurrent and complicated urinary infections are already the company's clearest clinical use case. That expansion can reuse laboratory infrastructure, genomic references, software, provider relationships, and regulatory experience, but each new assay still needs evidence and a defined clinical role.

Orthopedics adds a different specimen and care pathway. Biotia is working with Hospital for Special Surgery on BIOTIA-ID Joint Fluid for joint infections. The product is currently labeled research-use only, so the financing supports a development direction rather than a finished clinical launch.

The company has also announced a collaboration with Mayo Clinic on microbial identification. These institutional relationships can help shape validation and clinical application, but Biotia has not disclosed commercial economics, deployment volume, or revenue from the partnerships.

The investors and governance around the next stage

Tim Barry and Clive Fields joined investors including Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, and Red Bear Ventures in the financing. The October 1 announcement did not identify a lead or disclose individual check sizes.

Biotia also expanded the healthcare experience around its board and advisory group. Michele Colucci, CEO of DigitalDx Ventures, is board chair; VillageMD co-founder Tim Barry joined as a board member; and VillageMD co-founder Clive Fields joined as a board observer. Angelish Kumar, Lesley Northrop, and Catherine Balsam-Schwaber joined as advisors across chronic UTI care, diagnostics operations, and women's-health commercialization.

Biotia previously raised an oversubscribed $8M Series A in August 2022 led by OCA Ventures. The company has not published a complete cumulative financing total, so the current transaction should be read as a new $9M financing rather than an inferred Series B or an exact total-capital milestone.

What the $9M changes

The financing gives Biotia more capacity to turn clinical metagenomics from a technically credible assay into a repeatable care product. That requires more than sequencing instruments or software. It requires laboratory throughput, reimbursement evidence, clinician confidence, patient access, careful interpretation, and new-product validation moving at compatible speeds.

For operators and investors, Biotia offers a useful view of where diagnostics companies become difficult to build. The science can make a hidden pathogen visible, but the company still has to make the answer usable inside healthcare. This $9M is aimed at that less glamorous handoff, where evidence meets the laboratory, the claim, the clinician, and the next patient sample.